Pyramid Feature Iterative Fusion: A Cross-Scale Fusion Algorithm for Enhanced Analysis of H&E Images in HER2-Positive Breast Cancer

被引:0
|
作者
Xiong, Xiaomin [1 ]
Zhang, Yuqi [2 ]
Gu, Lihua [3 ]
Li, Yi [1 ]
Lin, Bo [4 ]
Lei, Dajiang [2 ]
Wang, Guoyin [2 ]
Xu, Bo [4 ]
机构
[1] Chongqing Univ, Sch Med, Chongqing, Peoples R China
[2] Chongqing Univ Posts & Telecommun, Chongqing, Peoples R China
[3] Chongqing Univ Posts & Telecommun, Chongqing City Management Coll, Chongqing, Peoples R China
[4] Chongqing Univ, Chongqing Key Lab Intelligent Oncol Breast Canc, Canc Hosp, Chongqing, Peoples R China
基金
中国国家自然科学基金;
关键词
HER2-positive breast cancer; Hematoxylin and Eosin (H&E) images; Convolutional Neural Network; Cross-scale Interpretability;
D O I
10.1109/ICDMW60847.2023.00045
中图分类号
TP18 [人工智能理论];
学科分类号
081104 ; 0812 ; 0835 ; 1405 ;
摘要
For HER2-positive breast cancer patients, the presence of distant metastasis is a crucial prognostic element. Early detection can notably assist in devising treatment strategies, thereby improving patient prognosis. Pathological Hematoxylin and Eosin (H&E) whole-slide images (WSIs) provide a rich array of prognosis-related histological features. By conducting an exhaustive multi-scale analysis, a hierarchical model embodying core tumor trait can be established. Currently, prevalent techniques in multi-scale H&E image analysis entail concatenating feature vectors and applying attention mechanisms to calculate feature correlations. Nonetheless, due to insufficient cross-scale correlation constraints, these methods might generate redundant information. This paper introduces Pyramid Feature Iterative Fusion (PFIF), a groundbreaking cross-scale fusion algorithm for H&E images. PFIF resolves the issues of redundancy and reduces noise following fusion. By integrating a backward feature fusion module, it emulates human evaluation of H&E images across scales. It amalgamates structural semantic features from a low-magnification view with texture features from a highmagnification view, thereby conveying key complementary details across resolutions. Training this model with H&E image data from Chongqing University's Cancer Hospital resulted in an AUC rate improvement of approximately 3.69.
引用
收藏
页码:311 / 317
页数:7
相关论文
共 36 条
  • [22] Patient (pt) preference and satisfaction with the subcutaneous fixed-dose combination of pertuzumab (P) and trastuzumab (H) in pts with HER2-positive early breast cancer (HER2+eBC): Interim analysis of the open-label, randomised cross-over PHranceSCa study
    O'Shaughnessy, J.
    Sousa, S. P.
    Cruz, J.
    Fallowfield, L. J.
    Auvinen, P.
    Pulido, C.
    Cvetanovic, A.
    Wilks, S.
    Ribeiro, L.
    Burotto, M.
    Klingbiel, D.
    Messeri, D.
    Alexandrou, A.
    Trask, P.
    Fredriksson, J.
    Stamatovic, L.
    ANNALS OF ONCOLOGY, 2020, 31 : S42 - S42
  • [23] Adjuvant trastuzumab emtansine (T-DM1) vs trastuzumab (H) in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: KATHERINE subgroup analysis
    Mano, Max S.
    Loibl, Sibylle
    Mamounas, Eleftherios P.
    von Minckwitz, Gunter
    Huang, Chiun-Sheng
    Untch, Michael
    Wolmark, Norman
    Wapnir, Irene L.
    Yang, Youngsen
    Conlin, Alison K.
    Kuemmel, Sherko
    Saghatchian, Mahasti
    DiGiovanna, Michael P.
    Strunk, Claudia
    Zimovjanova, Martina
    Song, Chunyan
    Liu, Haying
    Tesarowski, David
    Blotner, Steven
    Lam, Lisa H.
    Smitt, Melanie
    Geyer, Charles E., Jr.
    CANCER RESEARCH, 2020, 80 (04)
  • [24] HIGH EFFICACY OF THE COMBINATION CHEMOTHERAPY (CT) OF ORAL VINORELBINE (NVBO) AND CAPECITABINE (X) WITH TRASTUZUMAB (H) IN HER2-POSITIVE METASTATIC BREAST CANCER (MBC): UPDATED ANALYSIS OF THE RESULTS OF AN INTERNATIONAL PHASE II TRIAL
    Chan, A.
    Ganju, V.
    Becquart, D.
    Conte, P.
    Gil, M. Gil
    Petruzelka, L.
    Bernardo, G.
    Villanova, G.
    Tubiana-Mathieu, N.
    ANNALS OF ONCOLOGY, 2008, 19 : 68 - 68
  • [25] Integrated analysis of multidimensional genomic data on CALGB 40601 (Alliance), a randomized neoadjuvant phase III trial of weekly paclitaxel (T) and trastuzumab (H) with or without lapatinib (L) for HER2-positive breast cancer
    Tanioka, M.
    Fan, C.
    Carey, L. A.
    Hyslop, T.
    Pitcher, B. N.
    Parker, J. A.
    Hoadley, K. A.
    Henry, N. L.
    Tolaney, S.
    Dang, C.
    Krop, I. E.
    Harris, L.
    Berry, D. A.
    Mardis, E.
    Perou, C. M.
    Winer, E. P.
    Hudis, C. A.
    CANCER RESEARCH, 2017, 77
  • [26] Phase II study of the combination of oral vinorelbine (NVBo), capecitabine (X), and transtuzumab (H) in HER2-positive, metastatic breast cancer (MBC): Recent analysis of the results with a median follow-up of 44 months.
    Petruzelka, L. B.
    Ganju, V.
    Becquart, D.
    Conte, P. F.
    Tubiana-Mathieu, N.
    Gil, M. J. Gil
    Morand, M.
    Vaissiere, N.
    Villanova, G.
    Chan, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [27] Doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) with or without trastuzumab (H) as adjuvant therapy for patients with HER2-positive operable breast cancer (BC): combined analysis of NSABP B-31 and NCCTG N9831
    Romond, E. H.
    Perez, E. A.
    Bryant, J.
    Suman, V.
    Geyer, C. E.
    Davidson, N.
    Paik, S.
    Martino, S.
    Kaufman, P.
    Wolmark, N.
    EJC SUPPLEMENTS, 2005, 3 (02): : 73 - 73
  • [28] Cardiac safety and clinical activity of pegylated liposomal doxorubicin (D) and docetaxel (T) with and without trastuzumab (H) as 1st line chemotherapy in HER2-positive and HER2-negative metastatic breast cancer (MBC):: Eastern Cooperative Oncology Group (ECOG) trial E3198.
    Woff, AC
    Wang, M
    Sparano, JA
    Pins, MR
    Thor, AD
    Davidson, NE
    BREAST CANCER RESEARCH AND TREATMENT, 2004, 88 : S125 - S125
  • [29] Preliminary analysis of an expanded access study of the fixed-dose combination of pertuzumab (P) and trastuzumab (H) for subcutaneous injection (PH FDC SC) for at-home administration (admin) in patients (pts) with HER2-positive (HER2+) breast cancer (BC) during the COVID-19 pandemic.
    Dang, Chau T.
    Tolaney, Sara M.
    Riaz, Fauzia
    Tan, Antoinette R.
    Tkaczuk, Katherine H. R.
    Yu, Anthony Francis
    Liu, Jennifer
    Fung, Anita M.
    Yang, Anna
    Day, Bann-Mo
    Rugo, Hope S.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [30] Final overall survival (OS) analysis of PHEREXA: A randomized phase III trial of trastuzumab (H) plus capecitabine (X) ± pertuzumab (P) in patients with HER2-positive metastatic breast cancer (MBC) who experienced disease progression during or after H-based therapy
    Urruticoechea, Ander
    Rizwanullah, Mohammed
    Im, Seock-Ah
    Ruiz, Antonio Carlos Sanchez
    Lang, Istvan
    Tomasello, Gianluca
    Douthwaite, Hannah
    Crnjevic, Tanja Badovinac
    Heeson, Sarah
    Eng-Wong, Jennifer
    Munoz, Montserrat
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)